Mynvax Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 34

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $5.63M

  • Investors
  • 15

Mynvax General Information

Description

Developer of novel drugs designed to be used in vaccines for respiratory viruses. The company's drugs specialize in the treatment of flu and infectious diseases for the healthcare industry, enabling medical professionals to improve their patients' recovery.

Contact Information

Website
www.mynvax.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Brigade MLR Centre, Number 50, 3rd Floor
  • Vani Vilas Road, Basavanagudi
  • Bangalore, Karnataka 560004
  • India
+91 080
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Brigade MLR Centre, Number 50, 3rd Floor
  • Vani Vilas Road, Basavanagudi
  • Bangalore, Karnataka 560004
  • India
+91 080

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mynvax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 24-May-2024 $5.63M Completed Clinical Trials - Phase 2
6. Early Stage VC (Series A) 19-Jul-2021 Completed Pre-Clinical Trials
5. Early Stage VC 08-Jul-2020 Completed Pre-Clinical Trials
4. Early Stage VC 30-Oct-2019 Completed Startup
3. Equity Crowdfunding Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Mynvax’s complete valuation and funding history, request access »

Mynvax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 CCPS
Ordinary Shares
Preferance Shares
Ordinary Shares
Ordinary Shares 14,350 $0.119892 $117.54 $117.54 1x $117.54 24.33%
Ordinary Shares 667 $0.119892 $1.2 $1.2 1x $1.2 1.13%
To view Mynvax’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Mynvax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel drugs designed to be used in vaccines for respiratory viruses. The company's drugs specialize in the
Drug Discovery
Bangalore, India
34 As of 2026

Gurugram, India
 

Pune, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mynvax Competitors (5)

One of Mynvax’s 5 competitors is Premas Biotech, a Venture Capital-Backed company based in Gurugram, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Premas Biotech Venture Capital-Backed Gurugram, India
Serum Institute of India Private Equity-Backed Pune, India
BioNTech Formerly VC-backed Mainz, Germany
Bharat Biotech Formerly PE-Backed Hyderabad, India
Moderna Formerly VC-backed Cambridge, MA
You’re viewing 5 of 5 competitors. Get the full list »

Mynvax Patents

Mynvax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026083454-A1 Disulphide-linked oligomerization domain, polypeptides, and uses thereof Pending 19-Oct-2024
WO-2026069378-A1 Hemagglutinin based immunogenic polypeptides, compositions and methods thereof Pending 26-Sep-2024
WO-2024157279-A1 Stabilized immunogens derived from spike of coronavirus, compositions and methods thereof Inactive 23-Jan-2023
AU-2022425707-A1 Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof Pending 31-Dec-2021
EP-4456915-A1 Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof Pending 31-Dec-2021 A61K39/145
To view Mynvax’s complete patent history, request access »

Mynvax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mynvax Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
1Funds Domestic Scheme 1 Venture Capital Minority
Accel India Venture Capital Minority
AL Trust (India) Venture Capital Minority
Equirus Capital Investment Bank Minority
Inviga (Bangalore) PE/Buyout Minority
You’re viewing 5 of 15 investors. Get the full list »

Mynvax FAQs

  • When was Mynvax founded?

    Mynvax was founded in 2017.

  • Where is Mynvax headquartered?

    Mynvax is headquartered in Bangalore, India.

  • What is the size of Mynvax?

    Mynvax has 34 total employees.

  • What industry is Mynvax in?

    Mynvax’s primary industry is Drug Discovery.

  • Is Mynvax a private or public company?

    Mynvax is a Private company.

  • What is the current valuation of Mynvax?

    The current valuation of Mynvax is .

  • What is Mynvax’s current revenue?

    The current revenue for Mynvax is .

  • How much funding has Mynvax raised over time?

    Mynvax has raised $12.6M.

  • Who are Mynvax’s investors?

    1Funds Domestic Scheme 1, Accel India, AL Trust (India), Equirus Capital, and Inviga (Bangalore) are 5 of 15 investors who have invested in Mynvax.

  • Who are Mynvax’s competitors?

    Premas Biotech, Serum Institute of India, BioNTech, Bharat Biotech, and Moderna are competitors of Mynvax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process